Capital Analysts LLC Has $2.96 Million Stake in Danaher Co. (NYSE:DHR)

Capital Analysts LLC lifted its holdings in Danaher Co. (NYSE:DHR) by 20.8% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 12,801 shares of the conglomerate’s stock after acquiring an additional 2,205 shares during the quarter. Capital Analysts LLC’s holdings in Danaher were worth $2,961,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DHR. Keel Point LLC lifted its stake in Danaher by 11.8% in the fourth quarter. Keel Point LLC now owns 17,285 shares of the conglomerate’s stock valued at $3,999,000 after purchasing an additional 1,827 shares during the last quarter. Bourgeon Capital Management LLC raised its holdings in Danaher by 6.3% during the 4th quarter. Bourgeon Capital Management LLC now owns 55,683 shares of the conglomerate’s stock valued at $12,882,000 after acquiring an additional 3,289 shares during the period. Invesco LLC raised its holdings in Danaher by 22.0% during the 4th quarter. Invesco LLC now owns 1,309 shares of the conglomerate’s stock valued at $303,000 after acquiring an additional 236 shares during the period. Ballast Advisors LLC raised its holdings in Danaher by 64.7% during the 4th quarter. Ballast Advisors LLC now owns 3,218 shares of the conglomerate’s stock valued at $744,000 after acquiring an additional 1,264 shares during the period. Finally, BOK Financial Private Wealth Inc. raised its holdings in Danaher by 56.9% during the 4th quarter. BOK Financial Private Wealth Inc. now owns 215 shares of the conglomerate’s stock valued at $50,000 after acquiring an additional 78 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In other news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Teri List sold 3,289 shares of the stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,957 shares of company stock worth $8,265,802. Company insiders own 10.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on DHR shares. Citigroup upped their price target on shares of Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. JPMorgan Chase & Co. upped their price target on shares of Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. KeyCorp upped their price target on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, Barclays upped their target price on shares of Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 10th. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $267.43.

Danaher Stock Performance

NYSE DHR opened at $240.02 on Tuesday. The company has a 50-day simple moving average of $249.58 and a two-hundred day simple moving average of $229.84. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $259.00. The firm has a market cap of $177.74 billion, a price-to-earnings ratio of 37.51, a PEG ratio of 3.65 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.18. The business had revenue of $6.41 billion during the quarter, compared to analyst estimates of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company’s revenue was down 10.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.87 earnings per share. On average, equities analysts forecast that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date is Wednesday, March 27th. Danaher’s dividend payout ratio is currently 16.90%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.